top of page
Developing Novel, First in Class Drugs, Treating and Preventing
Type 2 Diabetes, Based on a Core-Technology-Platform.
Pipeline IND in process
Type 2 Diabetes Drug
Professor Chevion and co-inventors developed a family of non-steroidal chemical complexes, made of components approved for clinical use.
These New Chemical Entities constitute a protected PLATFORM of DRUGS, with proven efficacy and complete safety, for treatments of multiple indications. Concenter BioPharma is developing and commercializing the drug which treats and prevents Type 2 Diabetes.
The drug has 3 synergistic Mechanisms of Action, extensively tested in animal models of human diseases
(and anecdotal human cases).
Prof. DeFronzo presentation audio at the 17th World Congress
on Insulin Resistance. Diabetes & Cardiovascular Disease 
Insulin Resistance All You Wanted to KnowProf. DeFronzo
ABOUT US & VISION
Becoming a global specialty biopharmaceutical company by advancing a pipeline of products that demonstrate vast potential for treating TYPE 2 DIABETES.
Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications.
Our PLATFORM is the result of extensive investigation of animal models of human diseases.
MEMBERS OF OUR PLATFORM ACT AS:
Potent anti-inflammatory agents, Strong iron-chelating agents, and Anti-biotic agents.
To rapidly advance from laboratory experiments to clinical trials in Type 2 Diabetes based on "shortcut"
regulatory routes, that enable a shorter time from the lab to treating patients.
Our initial focus is on a leveraging Expedited Pathway programs.
Our focus leverages the global demand-creating patient population of about 570 million people with Diabetes.
Our drug for treating Type 2 Diabetes (Pill) – extensively demonstrated as effective in both prevention and treatment of T2 Diabetes – by Restoring Insulin Resistance to Normal Levels!
Markedly inhibiting the appearance and the degree of hyperglycemia; lowering LDL; lowering body weight; reduction of cataract formation and diabetes-induced retinopathy.
Our Stay Tuned Emails...
Let The News
Come To You.
When you subscribe to our Stay Tuned emails,
the personal information you provide is used only to send the information you requested.
We will not share your personal data with any third party.
bottom of page